6 papers in the library · 93 citations · publishing 2023-2026
JAMA July 1, 2026 I Glenn Cohen, Holly Fernandez Lynch, Al Mcguire
This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.
Psychedelic Medicine April 23, 2026 Jill Oliver Robinson, Ruiying (aria) Xiong, Logan Neitzke-Spruill et al.
Background: Institutional review boards (IRBs) are gatekeepers of psychedelic research, deciding whether and under what conditions it may proceed. Yet IRB understanding, attitudes, perspectives, and concerns regarding psychedelics and psychedelic research have not previously been studied. These factors are important to assessing whether US IRBs are likely to be over- or underprotective of...
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 2026 Holly Fernandez Lynch, Xinping Hu, Alison Bateman-House 2 citations
Psychedelic medicines hold the promise of therapeutic benefit for many suffering from serious unmet mental health needs, leading to substantial demand even before these drugs receive FDA approval based on demonstrated safety and effectiveness for particular conditions. Recognizing FDA approval as the ideal path for psychedelics intended for medical use and drawing on lessons from medical...
American Journal of Bioethics May 2, 2024 Edward Jacobs, Brian D. Earp, Paul S. Appelbaum et al. 29 citations
The first Hopkins-Oxford Psychedelic Ethics (HOPE) workshop convened to discuss ethical matters relating to psychedelics in August 2023 at the University of Oxford.The organizers (BDE, DBY, EJ) aim...
Science April 27, 2023 Amy L. Mcguire, Holly Fernandez Lynch, Lewis A. Grossman et al. 20 citations
Policy must support generation of evidence on safety and effectiveness.
AJOB Neuroscience 2023 Andrew Peterson, Emily A Largent, Holly Fernandez Lynch et al. 42 citations
In this paper, we examine the case of psychedelic medicine for Alzheimer's disease and related dementias (AD/ADRD). These "mind-altering" drugs are not currently offered as treatments to persons with AD/ADRD, though there is growing interest in their use to treat underlying causes and associated psychiatric symptoms. We present a research agenda for examining the ethics of psychedelic medicine...